A prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of SRT(Selective Retina Therapy) with 'R:GEN' in patients with Central Serous Chorioretinopathy

The Catholic University of Korea, Yeouido St. Mary's Hospital0 个研究点目标入组 44 人开始时间: 待定最近更新: 2021年7月12日

适应症

试验速览

暂无简介。

•In chronic CSC patients, as follows: (1) the eye with persistent ( = 3 months) subretinal fluid (SRF) involving the fovea in the optical coherence tomography (OCT) images of; (2) focal or diffuse active hyperfluorescent leakages due to CSC on the fundus fluorescein angiography (FFA) image; (3) between the age of 19 and 65 years.

•(1) the eye with best-corrected visual acuity (BCVA) of 20/200 or worse (Snellen equivalent); (2) other chorioretinal diseases such as choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV); (3) lens or vitreous opacity interrupting proper retinal imaging and laser treatment; (4) RPE atrophy over 1,000 µm in diameter involving fovea; (5) large PED over 300 µm in width or 100 µm in height; (6) history of conventional laser photocoagulation or PDT for CSC; (7) history of intravitreal injection of anti-VEGF within 10 weeks prior to SRT; (8) Use of systemic, periocular, intraocular corticosteroid within 1 year prior to SRT; (9) use of spironolactone, acetazolamide, or ketoconazole within 2 months prior to SRT.

发起方